AcelRx Pharmaceuticals, Inc

(NASDAQ:ACRX)

Latest On AcelRx Pharmaceuticals, Inc (ACRX):

Date/Time Type Description Signal Details
2023-05-11 01:31 ESTNewsAcelRx Pharmaceuticals GAAP EPS of -$0.75 beats by $0.04N/A
2023-05-11 01:30 ESTNewsAcelRx Pharmaceuticals, Inc. (ACRX) Q1 2023 Earnings Call TranscriptN/A
2023-05-09 23:31 ESTNewsAcelRx Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-04-13 16:31 ESTNewsAcelRx Pharmaceuticals: Taking Stock (But Not Currently Buying It)N/A
2023-03-31 00:31 ESTNewsAcelRx Pharmaceuticals GAAP EPS of $1.00 beats by $1.51, revenue of $0.25M misses by $4.25MN/A
2023-03-31 00:30 ESTNewsAcelRx Pharmaceuticals Inc. (ACRX) Q4 2022 Earnings Call TranscriptN/A
2023-03-30 00:16 ESTNewsAcelRx Pharmaceuticals Q4 2022 Earnings PreviewN/A
2023-03-14 16:16 ESTNewsAcelRx adds 16% on plans to divest pain therapyN/A
2022-12-27 18:02 ESTNewsAcelRx announces $7.5M direct offering of common stock and warrantsN/A
2022-12-08 21:02 ESTNewsAcelRx Pharma rises8% on positive data from post-operative pain management therapyN/A
2022-11-15 14:33 ESTNewsAcelRx Pharmaceuticals, Inc. (ACRX) Q3 2022 Results - Earnings Call TranscriptN/A
2022-11-14 21:46 ESTNewsAcelRx Pharmaceuticals GAAP EPS of -$0.94 beats by $0.26, revenue of $0.51M misses by $0.12MN/A
2022-11-12 00:16 ESTNewsAcelRx Pharmaceuticals Q3 2022 Earnings PreviewN/A
2022-10-25 22:00 ESTNewsAcelRx announces 1-for-20 reverse stock split, shares drop 15% aftermarketN/A
2022-08-19 09:48 ESTNewsAcelRx: The Catalogue Of Catalysts - Including A Big One That Will Do Investors WellN/A
2022-08-12 14:17 ESTNewsAcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-12 14:16 ESTNewsAcelRx Pharma stock falls ~17% premarket after Q2 results, large runup in sharesN/A
2022-08-11 22:16 ESTNewsAcelRx PharmaceuticalsEPS of $0.48, revenue of $0.57M beats by $0.02MN/A
2022-08-11 05:30 ESTNewsAcelRx Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-06-06 15:46 ESTNewsInovio Pharma, Bionano Genomics among health care stocks to join Russell Microcap Index; Tonix Pharma, iBio to leaveN/A
2022-06-06 15:45 ESTNewsAcelRx Pharmaceuticals: Finally, Plan BN/A
2022-06-03 15:44 ESTNewsAcelRx Pharmaceuticals, Inc's. (ACRX) CEO Vincent Angotti on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-19 16:17 ESTNewsFDA reduces certain requirements under drug safety program for AcelRx's DsuviaN/A
2022-05-18 02:18 ESTNewsAcelRx Pharmaceuticals, Inc.'s (ACRX) CEO Vincent Angotti on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-17 02:46 ESTNewsAcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-16 07:45 ESTNewsAcelRx Pharmaceuticals GAAP EPS of -$0.06 in-line, revenue of $0.44M misses by $0.11MN/A
2022-05-10 22:47 ESTNewsAcelRx' sufentanil sublingual tablet reduces postoperative opioid requirementN/A
2022-03-17 00:18 ESTNewsAcelRx Pharmaceuticals: Making Sense Of The Q4 NumbersN/A
2022-03-14 23:01 ESTNewsAcelRx stock falls 15% after HC Wainwright downgrade on 'disappointing quarter'N/A
2022-03-12 01:31 ESTNewsAcelRx stock falls 18% following Q4 resultsN/A
2022-03-11 06:32 ESTNewsAcelRx Pharmaceuticals GAAP EPS of -$0.06 beats by $0.01, revenue of $0.2M misses by $1.65MN/A
2022-03-11 06:30 ESTNewsAcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-09 19:15 ESTNewsAcelRx Pharmaceuticals Q4 2021 Earnings PreviewN/A
2022-02-01 22:01 ESTNewsAcelRx announces data on pain drug sufentanil sublingual for use in awake plastic surgeryN/A
2022-01-14 19:32 ESTNewsAcelRx Pharmaceuticals: The Fog Is Getting ThickerN/A
2022-01-05 00:31 ESTNewsAcelRx: Battered And Bruised But Ready For Recovery In 2022N/A
2021-12-16 01:47 ESTNewsAcelRx Pharma's sufentanil reduces hospital stay, opioid utilization in joint replacement surgeryN/A
2021-11-15 19:48 ESTNewsAcelRx Pharma to acquire Lowell TherapeuticsN/A
2021-11-15 19:48 ESTNewsAcelRx launches ~$14M securities offeringN/A
2021-11-15 19:47 ESTNewsAcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q3 2021 Results - Earnings Call TranscriptN/A
2021-10-15 08:46 ESTNewsWarning: ACRX is at high risk of performing badlyN/A
2021-10-02 05:31 ESTNewsAcelRx Pharmaceuticals: Is Wayne Gretzky Right Or The Puck?N/A
2021-09-27 12:03 ESTNewsWarning: ACRX has been downgraded to Very BearishN/A
2021-09-22 20:26 ESTNewsWarning: ACRX has been downgraded to Very Bearish.N/A
2021-08-31 02:34 ESTNewsAcelRx touts benefit of Dsuvia for pain following outpatient plastic surgeryN/A
2021-08-18 04:03 ESTNewsVirpax Pharmaceuticals, Sesen Bio leads healthcare gainers; Qualigen Therapeutics, Sema4 among major losersN/A
2021-08-17 08:01 ESTNewsAcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-15 18:15 ESTNewsAcelRx Pharmaceuticals Q2 2021 Earnings PreviewN/A
2021-07-27 23:18 ESTNewsAcelRx Pharmaceuticals: How The Licensing Agreements Could Become A Shot In The ArmN/A
2021-07-20 18:04 ESTNewsAcelRx Pharmaceuticals: Moving Closer To An Attractive Risk-RewardN/A

About AcelRx Pharmaceuticals, Inc (ACRX):

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

ACRX Quotes by TradingView

See Advanced Chart

General

  • Name AcelRx Pharmaceuticals, Inc
  • Symbol ACRX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-Specialty & Generic
  • Full Time Employees 54
  • Fiscal Year EndDecember
  • IPO Date2011-02-14
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.acelrx.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 29.91
  • Enterprise Value Revenue 38.54
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.29
  • Next Year EPS Estimate $0.04
  • Next Quarter EPS Estimate -$0.08
  • Operating Margin -756%
  • Return on Assets -32%
  • Revenue 5.42 million
  • Earnings Per Share -$0.71
  • Revenue Per Share $0.06
  • Gross Profit -4633000
  • Quarterly Earnings Growth 55.4%
View More

Highlights

  • Market Capitalization 212.92 million
  • EBITDA -44968000
  • Analyst Target Price $5.21
  • Book Value Per Share -$0.23
View More

Share Statistics

  • Shares Outstanding 118.95 million
  • Shares Float 116.47 million
  • % Held by Insiders 211%
  • % Held by Institutions 26.93%
  • Shares Short 7.43 million
  • Shares Short Prior Month 7.81 million
  • Short Ratio 1.3
  • Short % of Float 7%
  • Short % of Shares Outstanding 7%
View More

Technicals

  • Beta 0.98
  • 52 Week High $2.94
  • 52 Week Low $0.7
  • 50 Day Moving Average 2.14
  • 200 Day Moving Average 1.69
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

AcelRx Pharmaceuticals, Inc (ACRX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

AcelRx Pharmaceuticals, Inc (ACRX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-16$N/A-$0.10-$0.100%
2020-09-302020-11-05$N/A-$0.10-$0.09-11.11%
2020-06-302020-08-10$N/A-$0.08-$0.1233.33%
2020-03-312020-05-11$386000-$0.20-$0.16-23.08%
2019-12-312020-03-16$475000-$0.18-$0.182.07%
2019-09-302019-11-07$N/A-$0.16-$0.2123.81%
2019-06-302019-08-05$941000-$0.16-$0.2329.2%
2019-03-312019-05-08$265000-$0.17-$0.2222.05%
2018-12-312019-03-07$613000-$0.18-$0.2115.45%
2018-09-302018-11-02$377000-$0.21-$0.20-3.5%
2018-06-302018-08-02$818000-$0.20-$0.19-5.26%
2018-03-312018-05-09$343000-$0.23-$0.258%
2017-12-312018-03-08$740000-$0.20-$0.212.44%
2017-09-302017-11-09$1.49 million-$0.28-$0.27-4.36%
2017-06-302017-08-01$2.66 million-$0.29-$0.28-2.84%
2017-03-312017-05-08$3.11 million-$0.34-$0.27-25%
2016-12-312017-03-02$6.44 million-$0.25-$0.23-9.83%
2016-09-302016-11-01$3.37 million-$0.25-$0.23-8.7%
2016-06-302016-07-28$4.53 million-$0.24-$0.21-15.38%
2016-03-312016-05-02$3.03 million-$0.24-$0.19-24.68%
2015-12-312016-03-07$1.73 million-$0.24-$0.13-84.62%
2015-09-302015-10-29$15.43 million$0.11-$0.23147.83%
2015-06-302015-08-03$1.92 million-$0.20-$0.2623.08%
2015-03-312015-05-04$181000-$0.23-$0.2817.86%
2014-12-312015-03-09$226000-$0.32-$0.30-6.67%
2014-09-302014-11-10$4.83 million-$0.13-$0.2240.91%
2014-06-302014-08-11$71000-$0.24-$0.267.69%
2014-03-312014-05-08$95000-$0.22-$0.234.35%
2013-12-312014-03-03$27.61 million-$0.20-$0.17-17.65%
2013-09-302013-11-05$548000-$0.26-$0.19-36.84%
2013-06-302013-08-12$407000-$0.22-$0.220%
2013-03-312013-05-08$940000-$0.34-$0.27-25.93%
2012-12-312013-03-12$1.68 million-$0.41-$0.40-2.5%
2012-09-302012-11-06$166000-$0.38-$0.380%
2012-06-302012-08-09$224000-$0.35-$0.3910.26%
2012-03-312012-05-08$329000-$0.36-$0.35-2.86%
2011-12-312012-03-20$624000-$0.33-$0.3915.38%
2011-09-302011-11-08$408000-$0.30-$0.339.09%
2011-06-302011-08-11$40000-$0.25-$0.3119.35%
2011-03-312011-05-12$N/A-$0.30-$0.22-36.36%
2010-12-312011-03-24$N/A-$0.18

AcelRx Pharmaceuticals, Inc (ACRX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

AcelRx Pharmaceuticals, Inc (ACRX) Chart:

AcelRx Pharmaceuticals, Inc (ACRX) News:

Below you will find a list of latest news for AcelRx Pharmaceuticals, Inc (ACRX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

AcelRx Pharmaceuticals, Inc (ACRX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest ACRX Trades:

Date Shares Price
Jun 13, 2022 5:48 PM EST100$0.202
Jun 13, 2022 6:11 PM EST100$0.1963
Jun 13, 2022 6:28 PM EST100$0.1999
Jun 13, 2022 7:46 PM EST100$0.2023
Jun 13, 2022 7:59 PM EST100$0.2036

AcelRx Pharmaceuticals, Inc (ACRX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-17EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1427925/999999999520001458/9999999995-20-001458-index.htm
2019-10-25UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1427925/000000000019014882/0000000000-19-014882-index.htm
2019-11-25UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1427925/000000000019015839/0000000000-19-015839-index.htm
2020-04-14UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1427925/000000000020003202/0000000000-20-003202-index.htm
2020-06-17UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1427925/000000000020005423/0000000000-20-005423-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1427925/000083423720008190/0000834237-20-008190-index.htm
2018-09-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000089924318023787/0000899243-18-023787-index.htm
2018-09-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000089924318023788/0000899243-18-023788-index.htm
2018-09-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000089924318023789/0000899243-18-023789-index.htm
2018-09-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000089924318023791/0000899243-18-023791-index.htm
2019-06-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000089924319015714/0000899243-19-015714-index.htm
2019-11-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000089924319026511/0000899243-19-026511-index.htm
2019-11-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000089924319026512/0000899243-19-026512-index.htm
2019-11-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000089924319026513/0000899243-19-026513-index.htm
2019-11-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000089924319026514/0000899243-19-026514-index.htm
2019-11-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000089924319026515/0000899243-19-026515-index.htm
2019-11-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000089924319027073/0000899243-19-027073-index.htm
2020-04-06S-4Registration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1427925/000119312520099615/0001193125-20-099615-index.htm
2020-04-21S-4/ARegistration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1427925/000119312520113700/0001193125-20-113700-index.htm
2020-04-22CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1427925/000119312520114914/0001193125-20-114914-index.htm
2020-04-24424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1427925/000119312520119040/0001193125-20-119040-index.htm
2020-04-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000119312520127754/0001193125-20-127754-index.htm
2020-04-30425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1427925/000119312520127755/0001193125-20-127755-index.htm
2020-05-27425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1427925/000119312520152447/0001193125-20-152447-index.htm
2020-05-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000119312520153197/0001193125-20-153197-index.htm
2020-05-27425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1427925/000119312520153198/0001193125-20-153198-index.htm
2020-05-29425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1427925/000119312520155101/0001193125-20-155101-index.htm
2020-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000119312520155941/0001193125-20-155941-index.htm
2020-05-29425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1427925/000119312520155942/0001193125-20-155942-index.htm
2018-08-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919118045578/0001209191-18-045578-index.htm
2018-08-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919118045581/0001209191-18-045581-index.htm
2018-08-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919118045663/0001209191-18-045663-index.htm
2018-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919118045839/0001209191-18-045839-index.htm
2018-09-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919118052334/0001209191-18-052334-index.htm
2018-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919118055123/0001209191-18-055123-index.htm
2018-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919118055127/0001209191-18-055127-index.htm
2018-11-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919118057212/0001209191-18-057212-index.htm
2018-11-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919118057250/0001209191-18-057250-index.htm
2018-11-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919118057251/0001209191-18-057251-index.htm
2018-11-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919118057252/0001209191-18-057252-index.htm
2018-11-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919118057255/0001209191-18-057255-index.htm
2018-11-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919118058155/0001209191-18-058155-index.htm
2018-11-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919118058807/0001209191-18-058807-index.htm
2018-11-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919118059292/0001209191-18-059292-index.htm
2018-12-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919118062333/0001209191-18-062333-index.htm
2018-12-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919118062870/0001209191-18-062870-index.htm
2018-12-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919118062871/0001209191-18-062871-index.htm
2019-02-075Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919119008170/0001209191-19-008170-index.htm
2019-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919119009806/0001209191-19-009806-index.htm
2019-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919119009812/0001209191-19-009812-index.htm
2019-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919119009816/0001209191-19-009816-index.htm
2019-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919119009820/0001209191-19-009820-index.htm
2019-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919119009822/0001209191-19-009822-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919119015612/0001209191-19-015612-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919119015617/0001209191-19-015617-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919119015622/0001209191-19-015622-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919119015629/0001209191-19-015629-index.htm
2019-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919119015634/0001209191-19-015634-index.htm
2019-03-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919119018711/0001209191-19-018711-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919119039017/0001209191-19-039017-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919119039018/0001209191-19-039018-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919119039019/0001209191-19-039019-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919119039020/0001209191-19-039020-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919119039022/0001209191-19-039022-index.htm
2019-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919119039023/0001209191-19-039023-index.htm
2019-08-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919119047417/0001209191-19-047417-index.htm
2019-11-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919119056002/0001209191-19-056002-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919120007738/0001209191-20-007738-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919120007739/0001209191-20-007739-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919120007740/0001209191-20-007740-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919120007741/0001209191-20-007741-index.htm
2020-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919120007742/0001209191-20-007742-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919120009161/0001209191-20-009161-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919120009162/0001209191-20-009162-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919120009163/0001209191-20-009163-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919120009164/0001209191-20-009164-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919120009168/0001209191-20-009168-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919120036726/0001209191-20-036726-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919120036729/0001209191-20-036729-index.htm
2020-06-154/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919120036749/0001209191-20-036749-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919120037075/0001209191-20-037075-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919120037077/0001209191-20-037077-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919120037078/0001209191-20-037078-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919120037079/0001209191-20-037079-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919120037080/0001209191-20-037080-index.htm
2020-06-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1427925/000120919120037082/0001209191-20-037082-index.htm
2018-06-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774918011855/0001437749-18-011855-index.htm
2018-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774918012799/0001437749-18-012799-index.htm
2018-07-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1427925/000143774918013207/0001437749-18-013207-index.htm
2018-07-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774918013208/0001437749-18-013208-index.htm
2018-07-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1427925/000143774918013303/0001437749-18-013303-index.htm
2018-07-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774918013304/0001437749-18-013304-index.htm
2018-08-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774918014307/0001437749-18-014307-index.htm
2018-08-0210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1427925/000143774918014328/0001437749-18-014328-index.htm
2018-11-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774918019403/0001437749-18-019403-index.htm
2018-11-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774918019417/0001437749-18-019417-index.htm
2018-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1427925/000143774918019481/0001437749-18-019481-index.htm
2018-11-09424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1427925/000143774918020163/0001437749-18-020163-index.htm
2018-11-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1427925/000143774918020621/0001437749-18-020621-index.htm
2018-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774918020624/0001437749-18-020624-index.htm
2019-01-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774919000739/0001437749-19-000739-index.htm
2019-02-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774919002640/0001437749-19-002640-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774919004327/0001437749-19-004327-index.htm
2019-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1427925/000143774919004353/0001437749-19-004353-index.htm
2019-03-07S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1427925/000143774919004354/0001437749-19-004354-index.htm
2019-04-3010-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1427925/000143774919008205/0001437749-19-008205-index.htm
2019-05-03PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1427925/000143774919008725/0001437749-19-008725-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774919009104/0001437749-19-009104-index.htm
2019-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1427925/000143774919009191/0001437749-19-009191-index.htm
2019-05-09424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1427925/000143774919009192/0001437749-19-009192-index.htm
2019-05-14DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1427925/000143774919009718/0001437749-19-009718-index.htm
2019-05-14DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1427925/000143774919009720/0001437749-19-009720-index.htm
2019-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774919011209/0001437749-19-011209-index.htm
2019-06-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774919012706/0001437749-19-012706-index.htm
2019-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774919015462/0001437749-19-015462-index.htm
2019-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1427925/000143774919015505/0001437749-19-015505-index.htm
2019-09-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774919019159/0001437749-19-019159-index.htm
2019-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774919021755/0001437749-19-021755-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1427925/000143774919021796/0001437749-19-021796-index.htm
2019-11-07CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1427925/000143774919021931/0001437749-19-021931-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774920000488/0001437749-20-000488-index.htm
2020-03-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774920005229/0001437749-20-005229-index.htm
2020-03-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774920005296/0001437749-20-005296-index.htm
2020-03-16425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1427925/000143774920005297/0001437749-20-005297-index.htm
2020-03-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1427925/000143774920005304/0001437749-20-005304-index.htm
2020-03-16S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1427925/000143774920005315/0001437749-20-005315-index.htm
2020-03-16425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1427925/000143774920005317/0001437749-20-005317-index.htm
2020-03-17425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1427925/000143774920005349/0001437749-20-005349-index.htm
2020-03-25425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1427925/000143774920006097/0001437749-20-006097-index.htm
2020-04-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774920007322/0001437749-20-007322-index.htm
2020-04-1710-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1427925/000143774920007965/0001437749-20-007965-index.htm
2020-04-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1427925/000143774920008376/0001437749-20-008376-index.htm
2020-04-24DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1427925/000143774920008378/0001437749-20-008378-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774920010284/0001437749-20-010284-index.htm
2020-05-11425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1427925/000143774920010285/0001437749-20-010285-index.htm
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1427925/000143774920010314/0001437749-20-010314-index.htm
2020-05-12425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1427925/000143774920010428/0001437749-20-010428-index.htm
2020-05-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774920011653/0001437749-20-011653-index.htm
2020-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774920012473/0001437749-20-012473-index.htm
2020-06-08POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1427925/000143774920012545/0001437749-20-012545-index.htm
2020-06-12S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1427925/000143774920013055/0001437749-20-013055-index.htm
2020-06-16S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1427925/000143774920013240/0001437749-20-013240-index.htm
2020-06-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774920013262/0001437749-20-013262-index.htm
2020-07-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1427925/000143774920014610/0001437749-20-014610-index.htm
2020-07-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1427925/000143774920014691/0001437749-20-014691-index.htm
2020-07-07CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1427925/000143774920014801/0001437749-20-014801-index.htm
2020-07-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774920015570/0001437749-20-015570-index.htm
2020-07-23424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1427925/000143774920015615/0001437749-20-015615-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774920017320/0001437749-20-017320-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1427925/000143774920017343/0001437749-20-017343-index.htm
2020-10-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774920020801/0001437749-20-020801-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1427925/000143774920022786/0001437749-20-022786-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1427925/000143774920022799/0001437749-20-022799-index.htm
2020-10-27SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1427925/000156761920018211/0001567619-20-018211-index.htm
2020-10-27SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1427925/000156761920018219/0001567619-20-018219-index.htm
2020-04-24EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1427925/999999999520000854/9999999995-20-000854-index.htm
2020-06-17EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1427925/999999999520001458/9999999995-20-001458-index.htm
2020-07-08EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1427925/999999999520001713/9999999995-20-001713-index.htm

AcelRx Pharmaceuticals, Inc (ACRX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of AcelRx Pharmaceuticals, Inc (ACRX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 211%
Institutional Ownership: 2693%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-02-11Badri N DasuChief Engineering OfficerBuy50,000.00104,061.00https://www.sec.gov/Archives/edgar/data/1427925/000120919119009820/0001209191-19-009820-index.htm
2020-06-16MARK A WANDirectorBuy7,500.0011,250.00https://www.sec.gov/Archives/edgar/data/1427925/000120919120037075/0001209191-20-037075-index.htm
2020-06-16STEPHEN J HOFFMANDirectorBuy7,500.0011,250.00https://www.sec.gov/Archives/edgar/data/1427925/000120919120037079/0001209191-20-037079-index.htm
2019-02-28Badri N DasuChief Engineering OfficerBuy9,206.002.8125,868.86113,267.00https://www.sec.gov/Archives/edgar/data/1427925/000120919119015629/0001209191-19-015629-index.htm
2019-02-11RAFFI ASADORIANChief Financial OfficerBuy68,750.00120,750.00https://www.sec.gov/Archives/edgar/data/1427925/000120919119009816/0001209191-19-009816-index.htm
2020-06-16Richard AfableDirectorBuy7,500.0012,250.00https://www.sec.gov/Archives/edgar/data/1427925/000120919120037082/0001209191-20-037082-index.htm
2019-02-28RAFFI ASADORIANChief Financial OfficerBuy3,647.002.8110,248.07124,397.00https://www.sec.gov/Archives/edgar/data/1427925/000120919119015634/0001209191-19-015634-index.htm
2020-02-06Lawrence G HamelChief Development OfficerBuy50,000.00133,382.00https://www.sec.gov/Archives/edgar/data/1427925/000120919120007738/0001209191-20-007738-index.htm
2018-08-07MARK G EDWARDSDirectorBuy5,300.002.8415,062.60160,300.00https://www.sec.gov/Archives/edgar/data/1427925/000120919118045839/0001209191-18-045839-index.htm
2020-02-06Badri N DasuChief Engineering OfficerBuy50,000.00163,267.00https://www.sec.gov/Archives/edgar/data/1427925/000120919120007741/0001209191-20-007741-index.htm
2020-06-15ADRIAN ADAMSDirectorBuy100,000.001.29128,900.00178,750.00https://www.sec.gov/Archives/edgar/data/1427925/000120919120036729/0001209191-20-036729-index.htm
2018-11-15MARK G EDWARDSDirectorBuy20,700.002.8258,376.07181,000.00https://www.sec.gov/Archives/edgar/data/1427925/000120919118058807/0001209191-18-058807-index.htm
2020-06-16ADRIAN ADAMSDirectorBuy7,500.00186,250.00https://www.sec.gov/Archives/edgar/data/1427925/000120919120037077/0001209191-20-037077-index.htm
2020-02-06RAFFI ASADORIANChief Financial OfficerBuy68,750.00196,689.00https://www.sec.gov/Archives/edgar/data/1427925/000120919120007739/0001209191-20-007739-index.htm
2019-03-12MARK G EDWARDSDirectorBuy19,000.002.9956,889.80200,000.00https://www.sec.gov/Archives/edgar/data/1427925/000120919119018711/0001209191-19-018711-index.htm
2019-06-25MARK G EDWARDSDirectorBuy3,750.00203,750.00https://www.sec.gov/Archives/edgar/data/1427925/000120919119039017/0001209191-19-039017-index.htm
2019-08-23MARK G EDWARDSDirectorBuy10,000.002.2021,956.00213,750.00https://www.sec.gov/Archives/edgar/data/1427925/000120919119047417/0001209191-19-047417-index.htm
2019-08-26MARK G EDWARDSDirectorBuy5,000.002.1710,849.50218,750.00https://www.sec.gov/Archives/edgar/data/1427925/000120919119047417/0001209191-19-047417-index.htm
2018-08-31Lawrence G HamelChief Development OfficerBuy6,876.001.4910,245.2424,371.00https://www.sec.gov/Archives/edgar/data/1427925/000089924318023787/0000899243-18-023787-index.htm
2019-11-12MARK G EDWARDSDirectorBuy25,000.001.7844,575.00243,750.00https://www.sec.gov/Archives/edgar/data/1427925/000120919119056002/0001209191-19-056002-index.htm
2020-06-16MARK G EDWARDSDirectorBuy7,500.00251,250.00https://www.sec.gov/Archives/edgar/data/1427925/000120919120037080/0001209191-20-037080-index.htm
2019-02-11Angotti Vincent J.Chief Executive OfficerBuy200,000.00254,650.00https://www.sec.gov/Archives/edgar/data/1427925/000120919119009806/0001209191-19-009806-index.htm
2019-02-28Angotti Vincent J.Chief Executive OfficerBuy3,234.002.819,087.54257,884.00https://www.sec.gov/Archives/edgar/data/1427925/000120919119015622/0001209191-19-015622-index.htm
2019-06-05Angotti Vincent J.Chief Executive OfficerBuy5,000.002.3111,550.00262,884.00https://www.sec.gov/Archives/edgar/data/1427925/000089924319015714/0000899243-19-015714-index.htm
2019-11-11Angotti Vincent J.Chief Executive OfficerBuy8,379.001.7914,973.27275,944.00https://www.sec.gov/Archives/edgar/data/1427925/000089924319027073/0000899243-19-027073-index.htm
2018-10-15Lawrence G HamelChief Development OfficerSell5,216.005.0026,080.0029,795.00https://www.sec.gov/Archives/edgar/data/1427925/000120919118055127/0001209191-18-055127-index.htm
2018-11-02Lawrence G HamelChief Development OfficerSell5,000.005.0025,000.0029,795.00https://www.sec.gov/Archives/edgar/data/1427925/000120919118057255/0001209191-18-057255-index.htm
2018-08-06RAFFI ASADORIANChief Financial OfficerBuy5,000.002.7513,725.0032,000.00https://www.sec.gov/Archives/edgar/data/1427925/000120919118045578/0001209191-18-045578-index.htm
2018-11-02Lawrence G HamelChief Development OfficerBuy5,000.002.2311,125.0034,795.00https://www.sec.gov/Archives/edgar/data/1427925/000120919118057255/0001209191-18-057255-index.htm
2018-08-07Angotti Vincent J.Chief Executive OfficerBuy10,000.002.9028,950.0035,000.00https://www.sec.gov/Archives/edgar/data/1427925/000120919118045663/0001209191-18-045663-index.htm
2018-09-24Lawrence G HamelChief Development OfficerSell6,953.004.5031,288.5035,011.00https://www.sec.gov/Archives/edgar/data/1427925/000120919118052334/0001209191-18-052334-index.htm
2019-06-25MARK A WANDirectorBuy3,750.003,750.00https://www.sec.gov/Archives/edgar/data/1427925/000120919119039023/0001209191-19-039023-index.htm
2019-06-25STEPHEN J HOFFMANDirectorBuy3,750.003,750.00https://www.sec.gov/Archives/edgar/data/1427925/000120919119039020/0001209191-19-039020-index.htm
2018-08-31Angotti Vincent J.Chief Executive OfficerBuy6,040.001.498,999.6041,040.00https://www.sec.gov/Archives/edgar/data/1427925/000089924318023788/0000899243-18-023788-index.htm
2018-08-31RAFFI ASADORIANChief Financial OfficerBuy10,000.001.4914,900.0042,000.00https://www.sec.gov/Archives/edgar/data/1427925/000089924318023789/0000899243-18-023789-index.htm
2018-08-06Pamela P PalmerChief Medical OfficerBuy37,000.002.75101,750.00456,134.00https://www.sec.gov/Archives/edgar/data/1427925/000120919118045581/0001209191-18-045581-index.htm
2020-06-15Angotti Vincent J.Chief Executive OfficerBuy7,547.001.3310,035.25468,757.00https://www.sec.gov/Archives/edgar/data/1427925/000120919120036726/0001209191-20-036726-index.htm
2018-11-13RAFFI ASADORIANChief Financial OfficerBuy5,000.003.1315,646.0047,000.00https://www.sec.gov/Archives/edgar/data/1427925/000120919118058155/0001209191-18-058155-index.htm
2018-11-19Pamela P PalmerChief Medical OfficerBuy16,000.003.0749,120.00472,134.00https://www.sec.gov/Archives/edgar/data/1427925/000120919118059292/0001209191-18-059292-index.htm
2019-06-25Richard AfableDirectorBuy3,750.004,750.00https://www.sec.gov/Archives/edgar/data/1427925/000120919119039019/0001209191-19-039019-index.htm
2020-02-06Angotti Vincent J.Chief Executive OfficerBuy200,000.00475,944.00https://www.sec.gov/Archives/edgar/data/1427925/000120919120007740/0001209191-20-007740-index.htm
2018-12-12Angotti Vincent J.Chief Executive OfficerBuy10,000.002.9929,890.0051,040.00https://www.sec.gov/Archives/edgar/data/1427925/000120919118062333/0001209191-18-062333-index.htm
2018-12-14RAFFI ASADORIANChief Financial OfficerBuy5,000.002.7813,883.0052,000.00https://www.sec.gov/Archives/edgar/data/1427925/000120919118062870/0001209191-18-062870-index.htm
2018-10-15Badri N DasuChief Engineering OfficerSell28,351.005.00141,755.0054,061.00https://www.sec.gov/Archives/edgar/data/1427925/000120919118055123/0001209191-18-055123-index.htm
2019-02-11Pamela P PalmerChief Medical OfficerBuy68,750.00540,884.00https://www.sec.gov/Archives/edgar/data/1427925/000120919119009812/0001209191-19-009812-index.htm
2019-02-28Pamela P PalmerChief Medical OfficerBuy840.002.812,360.40541,724.00https://www.sec.gov/Archives/edgar/data/1427925/000120919119015612/0001209191-19-015612-index.htm
2018-12-14Angotti Vincent J.Chief Executive OfficerBuy3,610.002.7810,023.5354,650.00https://www.sec.gov/Archives/edgar/data/1427925/000120919118062871/0001209191-18-062871-index.htm
2019-06-25Howard B RosenDirectorBuy3,750.0061,250.00https://www.sec.gov/Archives/edgar/data/1427925/000120919119039022/0001209191-19-039022-index.htm
2020-02-06Pamela P PalmerChief Medical OfficerBuy68,750.00612,907.00https://www.sec.gov/Archives/edgar/data/1427925/000120919120007742/0001209191-20-007742-index.htm
2020-06-16Howard B RosenDirectorBuy7,500.0068,750.00https://www.sec.gov/Archives/edgar/data/1427925/000120919120037078/0001209191-20-037078-index.htm
2019-02-11Lawrence G HamelChief Development OfficerBuy50,000.0074,371.00https://www.sec.gov/Archives/edgar/data/1427925/000120919119009822/0001209191-19-009822-index.htm
2019-02-28Lawrence G HamelChief Development OfficerBuy3,682.002.8110,346.4278,053.00https://www.sec.gov/Archives/edgar/data/1427925/000120919119015617/0001209191-19-015617-index.htm
2019-06-25ADRIAN ADAMSDirectorBuy3,750.0078,750.00https://www.sec.gov/Archives/edgar/data/1427925/000120919119039018/0001209191-19-039018-index.htm
2018-08-31Badri N DasuChief Engineering OfficerBuy8,022.001.4911,952.7882,412.00https://www.sec.gov/Archives/edgar/data/1427925/000089924318023791/0000899243-18-023791-index.htm